Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancerElaine T Lam, Matthew D Ringel, Richard T Kloos, et al.
Cancer Research|August 4, 2006
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patientsHeather Hampel, Wendy Frankel, Jenny Panescu, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
The Journal of Clinical Investigation|October 8, 2019
Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatmentDaniel M Ramos, Constantin d'Ydewalle, Vijayalakshmi Gabbeta, et al.
Muscle & Nerve|August 24, 2017
Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type IKristin J Krosschell, John T Kissel, Elise L Townsend, et al.
Blood|November 20, 2012
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutationsSebastian Schwind, Colin G Edwards, Deedra Nicolet, et al.
The New England Journal of Medicine|November 2, 2017
Single-Dose Gene-Replacement Therapy for Spinal Muscular AtrophyJerry R Mendell, Samiah Al-Zaidy, Richard Shell, et al.
JAMA|October 6, 2005
Somatic acquisition and signaling of TGFBR1*6A in cancerBoris Pasche, Thomas J Knobloch, Yansong Bian, et al.
Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.
The New England Journal of Medicine|June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationRichard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.
Pageof 8